6 Important Drug Safety Updates — 28 July 2026
- 28-07-2026
- Posted by: Eldaniz Hasanov
- Category: Uncategorized
PharmExpert LLC Pharmacovigilance Review | 28 July 2026
Our daily monitoring of official regulatory sources identified six updates of practical relevance to marketing authorisation holders and pharmacovigilance, quality and regulatory professionals.
1. FDA: Papaverine Hydrochloride Injection recall
American Regent is recalling lot 25202 of Papaverine Hydrochloride Injection, USP 60 mg/2 mL due to glass and/or paraformaldehyde particulates. Intravenous administration of contaminated product may cause local reactions, vascular obstruction in the heart, lungs or brain, stroke and death. No adverse events had been reported at the time of the FDA notice.
Importance: High — confirmed safety-related quality defect.
2. FDA: Cefazolin in Dextrose Injection recall
Baxter is recalling lot LD175708 of Cefazolin in Dextrose Injection, USP 2 g/100 mL due to cardboard particulate in the infusion solution. Potential consequences include pulmonary embolism, vascular occlusion, organ damage, phlebitis, immune activation and haemolysis.
Importance: High — the quality defect is directly associated with a significant patient risk.
3. FDA: Cyclophosphamide for Injection recall
Sunny Pharmtech is recalling lots C23019V1, C24015V1 and V24010V1 due to steel particulate. Potential outcomes include phlebitis, granulomas, vascular occlusion and life-threatening thromboembolic events. Oncology and immunocompromised patients may be particularly vulnerable.
Importance: High — there is a risk of serious harm, including death.
4. FDA: Cetirizine Hydrochloride Tablets 5 mg recall
Lots GY825029–GY825032 are being recalled due to potential cross-contamination with ranitidine. Patients with hypersensitivity may experience severe reactions including anaphylaxis, hypotension, breathing difficulties, swelling of the face or throat and loss of consciousness.
Importance: High — a potentially life-threatening risk has been documented.
5. Kazakhstan: new Pharmacovigilance information system
NDDA announced the start of pilot operation of the Pharmacovigilance information system on 20 July 2026. This is an important operational change in the national infrastructure for collecting and processing pharmacovigilance information.
Importance: Medium — operational change to the national PV system.
6. Ukraine: updated PSUR submission frequency information
The State Expert Center of the Ministry of Health of Ukraine updated its official information on the frequency of periodic safety update report submissions. The change is relevant to planning the regulatory obligations of marketing authorisation holders.
Importance: Medium — updated regulatory information on PSUR submissions.
Practical takeaway
A quality defect becomes pharmacovigilance-relevant when it is associated with a documented risk of patient harm. Rapid lot identification, quarantine, risk assessment, communication and documented corrective action are essential.
How PharmExpert LLC can help
PharmExpert LLC supports pharmaceutical companies across CIS and EAEU markets with regulatory intelligence monitoring, local pharmacovigilance, signal management, PSUR/PBRER and RMP support, safety communications, quality complaint assessment and end-to-end PV system outsourcing.
Explore our pharmacovigilance services or contact our team.
This material is based exclusively on official regulatory publications and is provided for informational purposes. It applies only to the specified lots and regulatory updates and does not constitute an assessment of the overall safety of any medicine or the activities of any manufacturer. The current regulatory status should always be verified using the official source.